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One Health (OH) Concept 
• Recognizes interrelationship between animal, human and 
environmental health, locally and globally. 
 
 
• Holistically embraces a very broad                                              
scope: biodiversity, rural development,                                               
food security, ecosystem sustainability,                                          
policy issues, wildlife diseases, etc..   
 
 
• Initiate worldwide strategies for                                            
interdisciplinary collaboration &                                        
communication in all aspect of                                 





• First discovered by Sir Griffith Evans in Punjab India (1880) 
• Haemoflagellated protozoa in both human and animals  
zoonotic vector-borne disease    
• Caused atypical human trypanosomiasis (AHT) in human and 
Surra disease in livestock 
• Wide variety of distributed vectors  easily spread worldwide  
• Drug resistant in some regions  suramin, pentamidine, berenil  
Vectors of Trypanosoma evansi 
Horsefly /Tabanus striatus Tsetse fly / Glossina morsitans 
Muscidae fly / Stomoxys spp. Horn fly / Haematobia spp. 
Triatominae bug / Triatoma spp. 
Buffalo leech / Hiruninaria manillensis  Vampire bat / Desmodus rotundus 
Another Possible Vectors of Trypanosoma evansi 
Argasidae tick / Ornithordorus spp. 
Documented AHT (Philippe et al. 2013) 
No Location Species / Subspecies Date Identification Method Fever Treatment Outcomes 
1 Ghana T. vivax 1917 Morphology ND ND ND 
2 Pasteur Inst. T. b. brucei 1930 Morphology ND ND ND 
3 Congo T. b. brucei 1947 Morphology Present None Self-cured 
4 Ethiopia T. b. brucei 1987 Morphology ND ND Cured 
5 Ghana T. b. brucei 2003 PCR Present None Self-cured 
6 Ivory Coast T. congolense 1998 PCR Present Pentamidine Cured 
7 India T. evansi 1977 Morphology Present Atoxyl Cured 
8 Sri Lanka T. evansi 1999 Morphology Present None Self-cured 
9 India T. evansi 2004 PCR Present Suramin Cured 
10 India  T. evansi 2005 Morphology Present None Death 
11 Egypt T. evansi 2010 Morphology Present ND Cured 
12 Malaysia T. lewisi 1933 Morphology Present None Self-cured 
13 India T. lewisi 1974 Morphology Present None Self-cured 
14 India T. lewisi 1974 Morphology Present None Self-cured 
15 Gambia T. lewisi-like 2003 PCR Present Melarsoprol Cured 
16 Thailand T. lewisi-like 2003 PCR Present Antibiotic Cured 
17 India T. lewisi 2006 Morphology Present None Self-cured 
18 India T. lewisi 2007 PCR Present Suramin Death 
19 India T. lewisi 2010 PCR Present Pentamidin Cured 
Elettaria cardamomum  
• Cardamom powder  therapeutic 
effects & significant biological 
activities (Gao et al.  2008) 
• “Queen of Spice”  South Asia, SEA, 
Middle East, Africa and Europe 
(Ravindran 2010) 
 
• In 100gm  300kcal, 68g CHO, 15g 
protein, 28g fibers & no cholesterol  
 
• Vitamin A & C, Na, K, Ca, Fe, Mn, P, 
Cu, Mg & Zn (Cox et al. 2000) 
   
In-vitro inhibits 87% - 95% of 
Leishmania amazonensis & 
L. braziliensis promatigotes 
growth (Denise at el. 2010) 
 
Inhibits the synthesis of 
peptidoglycan molecules in 
bilayer lipid structure of 
organism plasma membrane 
(Ogunlana et al. 2013) 
Cardamom oil exhibits anti-
gonorrhea and anti- nephritis 
property in male rabbit’s 
urethra (Turi et al. 2011) 
Anti-colorectal tumour with 
68% inhibition rate on human 
colon adenocarcinoma cells 
HCA-2 and HCA-7 (Gayathri 
et al. 2010) 
Curing asthma and bronchitis 
symptoms by increasing 
blood circulation to the lungs 
(Berhe et al. 2009) 
E. cardamomum: The Testimonies  
Cardamom powder  good 
therapeutic preventive effect 
and  significant biological 
activities (Gao et al.  2008) 

Experimental Materials 
T. evansi stock 




















Oral administered of 0.1 mL/mouse  of           
10 µg/mL of E. cardamomum-dH2O extract 
T. evansi administered i.p.  
(5 × 103 T. evansi / mice) 
Flow Chart 
Experimental Design 







PRE14 : 14 days pre-infection 0.1 mL of 10 µg/mL of dH2O-extract 
PRE07 : 7 days pre-infection 0.1 mL of 10 µg/mL of dH2O-extract 
PRE03 : 3 days pre-infection 0.1 mL of 10 µg/mL of dH2O-extract 
 
CURATIVE 
CUR03 : 3 days post-infection 0.1 mL of 10 µg/mL of dH2O-extract 
CUR05 : 5 days post-infection 0.1 mL of 10 µg/mL of dH2O-extract 
CUR07 : 7 days post-infection 0.1 mL of 10 µg/mL of dH2O-extract 
GROUP REGIME DESCRIPTION CONTROL DOSAGE 
 
CONTROL 
POSITIVE POS : Berenil (Sigma-Aldrich KL) 0.01 mL 3.5 mg/kg bw  
NEGATIVE NEG : 0.9 % Normal Saline 0.1 mL  0.9 normal saline 
LETHAL  LTN : Infection without treatment 5 × 103  T. evansi / mice (i.p.) 
METODOLOGI 
(A) (B) (C) 
(D) (E) (F) 
Parasite Administration And Animal Tagging  
(A) (B) (C) 
(D) 
Giemsa Staining And Microscopic Observation 
(E) (F) 
(A) 
Biochemical Test And Histology Of Liver & Kidney  
(E) 
(A) (B) (C) 
(D) (E) (F) 

Mice Survival Time (Day) 
















































Parasite Survival In PRE14 Mice Group : 50th Day 
Giemsa thin blood smear of the mice from PRE14 mice group taken on day 50 
post-infection as observed under x100 magnification of light microscope (A) 
and x5000 magnification of SEM (Phillips XL30, UK) (B) 
(A) (B) (B) 
DAY 50 
PARASITE SURVIVAL IN PRO1 GROUP: ON 115th DAY 
(A) (B) 
arasite Survival n PRE14 Mice Group 100th Day 
DAY 100 
Giemsa thin blood smear of the mice from PRE14 mice group taken on day 
100 post-infection as observed under x100 magnification of light microscope 
(A) and x5000 magnification of SEM (Phillips XL30, UK) (B) 
(A) (B) (B) 
Parasite Survival In PRE14 Mice Group : 150th Day 
DAY 150 
Giemsa thin blood smear of the mice from PRE14 mice group taken on day 
150 post-infection as observed under x100 magnification of light microscope 
(A) and x5000 magnification of SEM (Phillips XL30, UK) (B) 
(B) (A) ( ) 
Parasite Survival In PRE14 Mice Group : 200th Day 
DAY 200 
Giemsa thin blood smear of the mice from PRE14 mice group taken on day 
200 post-infection as observed under x100 magnification of light microscope 
(A) and x4000 magnification of SEM (Phillips XL30, UK) (B) 
(B) (A) ( ) 
Parasite Survival In PRE14 Mice Group : 250th Day 
DAY 250 
Giemsa thin blood smear of the mice from PRE14 mice group taken on day 
250 post-infection as observed under x100 magnification of light microscope 
(A) and x5000 magnification of SEM (Leo 1450VP, Japan) (B) 
(A) (B) 
DAY 270 
Parasite Survival In PRE14 Mice Group : 270th Day 
Giemsa thin blood smear of the mice from PRE14 mice group taken on day 
270 post-infection as observed under x100 magnification of light microscope 
(A) and x4600 magnification of SEM (Leo 1450VP, Japan) (B) 
(B) 
Parasite Growth in Berenil-Treated Group (POS) 
(1A) (2A) 
(1B) (2B) 




Parasite Growth in Berenil-Treated Group (POS) 
(4A) 
(4B) 
4th hour (5A) (6A) 
(5B) (6B) 
6th hour 5th hour 
(B) 
T. cucumerina VS Berenil  
(4B) (5B) (6B) 
(B) 
Scanning electron micrograph showed the morphological changes of                    
T. evansi in PRE14 mice (0.2 mL 100 mg/kg bw T. cucumerina aqueous-extract) 
on 270th day post infection (A) and in POS mice at 6th hours post treatment 
(0.01mL 3.5 mg/kg bw Berenil) (B) as observed under x5000 magnification of SEM  
(A) 
E. Cardamomum : 270th day Berenil : 6th hours 
Biochemical Test For Toxicity Assessment 
(A) 










41.03    
± 3.91 
44.83   
± 1.11 


















59.4     
± 2.97 
69.2     
± 2.90 




58.32   
± 2.97 
54 – 115 IU/L 
STP (*) 
6.12    
± 2.32 
7.21      
± 3.81 
7.93     
± 2.01 
8.83    
± 3.90 
6.40     
± 1.01 
6.80   
± 3.06 
5.8 – 9.5 g/dL 
TA : Sub-acute regime – Daily treatment (28 days)  
TB : Sub-acute regime – Daily treatment (28 days) 2 hours post-infection 
TC : Sub-chronic regime – Daily treatment (90 days) 
TD : Sub-chronic regime – Daily treatment (90 days) 2 hours post-infection 
CN : Control regime – Normal mice without infection and treatment 
CI : Control regime – Infected mice on D0 
ALT : Alanine aminotransferase 
AST : Aspartate transaminase 
ALP : Alkaline phosphatase 
STP : Serum total protein 
(*) All values were expressed as   
     mean ± standard deviation (sd) 




Control Treatment (Acute) Treatment (Sub-acute) 

Hypothesis 
• New wave of infection  mice is susceptible to infection (Kurup 
and Rajamohan 2011) 
 
• Curative regime are less effective than other  treatment regimens. 
 
• Longer prophylactic duration  longer survival period of the host. 
 
• A bioactivve compound, nerolidol in E. cardamomumm able to 
prolong the survival rate of the Leishmania-infected mice although 
the parasitemia density is high (Romão et al. 2006) 
 
• OH approaches within multidisciplinary collaboration is required to 










of T. cucumerina 
extract 
Concentration-  & 
time-dependant 
alteration  




against T. cruzi  
and T. brucei 
Absolute Hypothesis 
 
CONSUME CARDAMOM..!  
Absolute Hypothesis 

• Philippe, T., Philippe, Bu., Ge´rard, C., Mary, I.G., Jean, J., Prashant, J., Prayag, J., Zhao-Ron, L., Raffaele, M., 
Etienne, P., Pere, P.S., Marta-Maria, G. T., Louis, T., Philippe V. & Marc, D. 2013. Atypical Human Infections by 
Animal Trypanosomes. PLOS Neglected Tropical Disease. 7(9): e2256 
• Ravindran, M.K. 2002. Cardamom: the genus Elettaria. New York: Taylor and Francis. 
• Guidelines. Research Animal Resources, University of Minnesota. Available from: 
http://www.ahc.umn.edu/rar/refvalues.html. Accessed January 8, 2017. 
• Gayathri, B., Manjula, N., Vinaykumar, K.S., Lakshmi, B.S. & Balakrishnan, A. 2007. Pure compound from 
Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages 
through inhibition of TNFa, IL-1b, NO and MAP kinases. Int. Immunopharmacol. 7, 473-482. 
• Cox, S.D., Mann, J.L., Bell, J.E. & Warmington, S.G. 2000. The mode of antimicrobial action of the essential oil 
of Melaleuca alternifolia (tea tree oil). Journal of Applied Microbiology 88, 170–175. 
• Berhe, N., Wolday, D., Hailu, A., Abraham, Y., Ali, A., Gebre-Michael, T., Desjeux, P., Sonnerborg, A., Akuffo, H. 
& Britton, S. 1999. HIV viral load and response to lesishmanial chemotherapy in coinfected patients. AIDS 13: 
1921-192 
• Ogunlana, E.O., Hoeglund, S., Onawunmi, G. & Skoeld, O. 1987. Effects of lemongrass oil on the morphological 
characteristics and peptidoglycan synthesis of Escherichia coli cells. Microbios, 50, 43–59. 
• Zainal-Abidin, B.A.H. 1992. Infections of Trypanosoma evansi in Malaysia. Malays. Applied Biology 10: 1-8 
• Jones, K. E., Patel, N. G. & Levy, M. A. (2008). Global trends in emerging infectious diseases. Nature. 451: 990-
993 












• Arsad, S.S., Esa, N.M. & Hamzah, H. 2014. Histopathologic changes in liver and kidney tissues from male sprague 
dawley rats treated with Rhaphidophora decursiva (Roxb.) schott extract. J Cytol Histol. 4(1):10–18 
• Chen, H.C., Chang, M.D. & Chang, T.J. 1985. Antibacterial properties of some spice plants before and after heat 
treatment. Journal of Pharmacology. 18: 190-195. 
• Fevre, E.M., Coleman, P.G., Welburn, S.C. & Maudlin, I. 2004. Reanalyzing the 1900-1920 sleeping sickness 
epidemic in Uganda. Emerging infectious diseases. 10 (4). p. 567-571. 
• Mitsumari, K., Shibutani, S., & Sato, S. (1998). Relationship between the development of hepatorenal toxicity and 
cadmium accumulation in rats. Arch Toxicol. 72(9):545–552. 
• Romão, P.R.T., Tovar, J. Fonseca, S.G. Moraes, R.H., Cruz, A.K., Hothersall, J.S., -Noronha-Dutra, A.A., Ferreira, S.H. 
& Cunha, F.Q. 2006. Glutathione and the redox control system trypanothione/trypanothione reductase are 
involved in the protection of Leishmania spp. against nitrosothiol-induced cytotoxicity. Brazilian Journal of 
Medical and Biological Research 39(3): 355-363. 
• Talakal. T.S., Dwivedi, S.K. & Sharma, S R. 2000. in vitro and in vivo antitrypanosoma potential of nyctanthes 
arbor-tristis leaves. Pharmaceutical Biology. 38: 326-329 
• Wolfe, N.D., Dunavan, C.P. & Diamond, J. 2007. Origins of major human infectious diseases. Nature.  447: 279-283 
• Verma, B.B., Gautam, O.P. & Malik P.D. 1976. Trypanosoma evansi: therapeutic efficacy of diaminazine aceturate 
in crossbred calves, Bos Taurus and B. indicus. Experimental Parasitology 40: 406-410. 
• Taylor, L.H., Latham, S.M. & Woolhouse, M.E. 2001. Risk Factors for Human Disease Emergence. Philos Trans R Soc 
Lond B Biol Sci. 356(1411): 983-989 
• Anonymous. 2003. Universiti Kebangsaan Malaysia Animal Ethics Committee Guidelines (UKMAEC). UKMAEC 
Secretariat, Kuala Lumpur, 1-40 
R
e
fe
r
e
n
c
e
s
  



